Ovarian low-grade serous carcinoma: A comprehensive update

被引：63

作者：

Diaz-Padilla, Ivan ^{[1
,2
]}

Malpica, Anais L. ^{[3
]}

Minig, Lucas ^{[4
]}

Chiva, Luis M. ^{[5
]}

Gershenson, David M. ^{[6
]}

Gonzalez-Martin, Antonio ^{[7
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] Hosp Univ Madrid, Ctr Integral Oncol Clara Campal, Div Med Oncol, Madrid, Spain

[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[4] Hosp Univ Madrid, Ctr Integral Oncol Clara Campal, Gynecol Oncol Program, Dept Gynecol & Obstet, Madrid, Spain

[5] MD Anderson Canc Ctr, Dept Gynecol Oncol, Madrid, Spain

[6] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA

[7] Div Med Oncol, MD Anderson Canc Ctr, Madrid, Spain

来源：

GYNECOLOGIC ONCOLOGY | 2012年 / 126卷 / 02期

关键词：

Serous ovarian cancer; Low-grade; RAS; MEK inhibitors; Cytoreductive surgery; QUALITATIVE AGE INTERACTIONS; ACTIVATED PROTEIN-KINASE; PHASE-II; NEOADJUVANT CHEMOTHERAPY; MUTATIONAL ANALYSIS; CLINICAL BEHAVIOR; BRAF MUTATION; CANCER; EXPRESSION; STAGE;

D O I：

10.1016/j.ygyno.2012.04.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian low-grade serous ovarian carcinoma (OvLGSCa) comprises a minority within the heterogeneous group of ovarian carcinomas. Despite biological differences with their high-grade serous counterparts, current treatment guidelines do not distinguish between these two entities. OvLGSCas are characterized by an indolent clinical course. They usually develop from serous tumors of low malignant potential, although they can also arise de novo. When compared with patients with ovarian high grade serous carcinoma (OvHGSCa) patients with OvLGSCa are younger and have better survival outcomes. Current clinical and treatment data available for OvLGSCa come from retrospective studies, suggesting that optimal cytoreductive surgery remains the cornerstone in treatment, whereas chemotherapy has a limited role. Molecular studies have revealed the preponderance of the RAS-RAF-MAPK signaling pathway in the pathogenesis of OvLGSCa, thereby representing an attractive therapeutic target for patients affected by this disease. Improved clinical trial designs and international collaboration are required to optimally address the unmet medical treatment needs of patients affected by this disease. (C) 2012 Elsevier Inc. All rights reserved.

引用

页码：279 / 285

页数：7

共 73 条

[1] Qualitative age interactions (or effect modification) suggest different cancer pathways for early-onset and late-onset breast cancers [J].

Anderson, William F. ;

Chen, Bingshu E. ;

Brinton, Louise A. ;

Devesa, Susan S. .

CANCER CAUSES & CONTROL, 2007, 18 (10) :1187-1198

[2]

[Anonymous], 2011, CANC OV NCCN CLIN PR

[3]

Ansquer Y, 2001, CANCER, V91, P2329, DOI 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.3.CO

[4]

2-L

[5] Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein [J].

Armes, Jane E. ;

Lourie, Rohan ;

de Silva, Melanie ;

Stamaratis, Georgia ;

Boyd, Alison ;

Kumar, Beena ;

Price, Gareth ;

Hyde, Simon ;

Allen, David ;

Grant, Peter ;

Venter, Deon J. .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2005, 24 (04) :363-368

[6] Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas A Clinicopathologic and Molecular Genetic Analysis [J].

Ayhan, Ayse ;

Kurman, Robert J. ;

Yemelyanova, Anna ;

Vang, Russell ;

Logani, Sanjay ;

Seidman, Jeffrey D. ;

Shih, Ie-Ming .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (08) :1220-1224

[7] Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer [J].

Beauchamp, Marie-Claude ;

Yasmeen, Amber ;

Knafo, Ariane ;

Gotlieb, Walter H. .

JOURNAL OF ONCOLOGY, 2010, 2010

[8] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9] Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms [J].

Bidus, Michael A. ;

Webb, Joel C. ;

Seidman, Jeffrey D. ;

Rose, G. Scott ;

Boice, Charles R. ;

Elkas, John C. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (01) :5-7

[10] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. [J].

Bonome, T ;

Lee, JY ;

Park, DC ;

Radonovich, M ;

Pise-Masison, C ;

Brady, J ;

Gardner, GJ ;

Hao, K ;

Wong, WH ;

Barrett, JC ;

Lu, KH ;

Sood, AK ;

Gershenson, DM ;

Mok, SC ;

Birrer, MJ .

CANCER RESEARCH, 2005, 65 (22) :10602-10612

← 1 2 3 4 5 6 7 8 →